WCM Investment Management LLC Purchases 6,047 Shares of Glaukos Corporation $GKOS

Key Points

• WCM Investment Management LLC increased its stake in Glaukos Corporation by 6.2% during the second quarter, acquiring an additional 6,047 shares and owning 0.18% of the company, valued at approximately $10.43 million.
• Glaukos reported a negative earnings per share (EPS) of ($0.24) for the most recent quarter, beating the analyst consensus estimate of ($0.26), with a revenue increase of 29.7% year-over-year.
• Analysts have a consensus Moderate Buy rating for Glaukos shares, with an average price target of $116.92, reflecting positive sentiment despite mixed ratings from different brokerages.

WCM Investment Management LLC boosted its position in shares of Glaukos Corporation (NYSE:GKOS - Free Report) by 6.2% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 102,870 shares of the medical instruments supplier's stock after purchasing an additional 6,047 shares during the period. WCM Investment Management LLC owned about 0.18% of Glaukos worth $10,433,000 at the end of the most recent reporting period.

Other hedge funds also recently modified their holdings of the company. Bessemer Group Inc. grew its holdings in shares of Glaukos by 133.9% in the 1st quarter. Bessemer Group Inc. now owns 276 shares of the medical instruments supplier's stock valued at $27,000 after acquiring an additional 158 shares in the last quarter. First Horizon Advisors Inc. grew its holdings in shares of Glaukos by 72.9% in the 1st quarter. First Horizon Advisors Inc. now owns 377 shares of the medical instruments supplier's stock valued at $37,000 after acquiring an additional 159 shares in the last quarter. Park Place Capital Corp grew its holdings in shares of Glaukos by 68.4% in the 2nd quarter. Park Place Capital Corp now owns 399 shares of the medical instruments supplier's stock valued at $41,000 after acquiring an additional 162 shares in the last quarter. Bayforest Capital Ltd bought a new position in shares of Glaukos in the 1st quarter valued at about $141,000. Finally, Revisor Wealth Management LLC bought a new position in shares of Glaukos in the 2nd quarter valued at about $204,000. Institutional investors own 99.04% of the company's stock.

Glaukos Trading Down 0.3%

Shares of NYSE:GKOS opened at $85.34 on Friday. Glaukos Corporation has a 52-week low of $77.10 and a 52-week high of $163.71. The company has a market capitalization of $4.89 billion, a P/E ratio of -51.72 and a beta of 0.76. The company has a 50-day simple moving average of $87.69 and a 200 day simple moving average of $92.29. The company has a debt-to-equity ratio of 0.09, a quick ratio of 4.69 and a current ratio of 5.51.

Glaukos (NYSE:GKOS - Get Free Report) last issued its quarterly earnings data on Wednesday, July 30th. The medical instruments supplier reported ($0.24) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.26) by $0.02. The firm had revenue of $124.12 million during the quarter, compared to the consensus estimate of $115.49 million. Glaukos had a negative net margin of 21.43% and a negative return on equity of 8.59%. The business's revenue for the quarter was up 29.7% compared to the same quarter last year. During the same period last year, the business posted ($0.52) earnings per share. Glaukos has set its FY 2025 guidance at EPS. Sell-side analysts forecast that Glaukos Corporation will post -1.08 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on GKOS. Wells Fargo & Company raised their price objective on Glaukos from $86.00 to $92.00 and gave the company an "equal weight" rating in a report on Thursday, July 31st. Truist Financial decreased their price objective on Glaukos from $126.00 to $120.00 and set a "buy" rating for the company in a report on Monday, September 22nd. UBS Group raised their target price on shares of Glaukos from $125.00 to $134.00 and gave the company a "buy" rating in a research note on Thursday, July 31st. William Blair upgraded shares of Glaukos to a "strong-buy" rating in a research note on Thursday, July 31st. Finally, Weiss Ratings reiterated a "sell (d-)" rating on shares of Glaukos in a research note on Wednesday, October 8th. One research analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating, two have given a Hold rating and two have given a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average price target of $116.92.

Glaukos Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.

Want to see what other hedge funds are holding GKOS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Glaukos Corporation (NYSE:GKOS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.